Abstract
The more common sporadic form of Alzheimer disease (SAD) and the metabolic syndrome are two highly prevalent pathological conditions of Western society due to incorrect diet, lifestyle, and vascular risk factors. Due to the increasing aging of populations, prevalence of AD in western industrialized countries will rise in the near future and, thus, new knowledge in the area of molecular biology and epigenetics will probably help to reverse the neurodegenerative process. Recent data have suggested metabolic syndrome as an independent risk factor for SAD. Furthermore, biological plausibility for this relationship has been framed within the metabolic cognitive syndrome concept, and some authors designed SAD as a brain diabetes or diabetes 3. Then, impaired signaling of insulin and from some adipokines involved in the so called adipoinsular axis, like leptin, ghrelin or amylin could give a metabolic basis to explain the origin and progression of SAD. Thus, dipokines like leptin, ghrelin and amylin, or their mimetic compounds, could contribuite to inhibit apoptosis and inflammation processes and, thus, generate protective responses in the nervous system. Moreover, these adipokines might promote the activation of a cognitive process which may retard or even partially reverse selected aspects of Alzheimer’s disease or ageing memory loss.
Keywords: Sporadic Alzheimer disease, adipokines, leptin, ghrelin, amylin, prolactin
Current Pharmaceutical Design
Title:Metabolic Basis of Sporadic Alzeimer’s Disease. Role of Hormones Related to Energy Metabolism
Volume: 19 Issue: 38
Author(s): Jaume Folch, Ignacio Pedrós, Iván Patraca, Nohora Martínez, Francesc Sureda and Antoni Camins
Affiliation:
Keywords: Sporadic Alzheimer disease, adipokines, leptin, ghrelin, amylin, prolactin
Abstract: The more common sporadic form of Alzheimer disease (SAD) and the metabolic syndrome are two highly prevalent pathological conditions of Western society due to incorrect diet, lifestyle, and vascular risk factors. Due to the increasing aging of populations, prevalence of AD in western industrialized countries will rise in the near future and, thus, new knowledge in the area of molecular biology and epigenetics will probably help to reverse the neurodegenerative process. Recent data have suggested metabolic syndrome as an independent risk factor for SAD. Furthermore, biological plausibility for this relationship has been framed within the metabolic cognitive syndrome concept, and some authors designed SAD as a brain diabetes or diabetes 3. Then, impaired signaling of insulin and from some adipokines involved in the so called adipoinsular axis, like leptin, ghrelin or amylin could give a metabolic basis to explain the origin and progression of SAD. Thus, dipokines like leptin, ghrelin and amylin, or their mimetic compounds, could contribuite to inhibit apoptosis and inflammation processes and, thus, generate protective responses in the nervous system. Moreover, these adipokines might promote the activation of a cognitive process which may retard or even partially reverse selected aspects of Alzheimer’s disease or ageing memory loss.
Export Options
About this article
Cite this article as:
Folch Jaume, Pedrós Ignacio, Patraca Iván, Martínez Nohora, Sureda Francesc and Camins Antoni, Metabolic Basis of Sporadic Alzeimer’s Disease. Role of Hormones Related to Energy Metabolism, Current Pharmaceutical Design 2013; 19 (38) . https://dx.doi.org/10.2174/13816128113199990612
DOI https://dx.doi.org/10.2174/13816128113199990612 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lower K<sub>V</sub>7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
CNS & Neurological Disorders - Drug Targets Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Nitrogen, Oxygen or Sulfur Containing Heterocyclic Compounds as Analgesic Drugs Used as Modulators of the Nitroxidative Stress
Mini-Reviews in Medicinal Chemistry An Appraisal of Current Pharmacological Perspectives of Sesamol: A Review
Mini-Reviews in Medicinal Chemistry Approaches to Mitochondrial Gene Therapy
Current Gene Therapy A Longitudinal Study of Alterations of S100B, sRAGE and Fas Ligand in Association to Olanzapine Medication in a Sample of First Episode Patients with Schizophrenia
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Potassium Channels (Guest Editor: Dr. Vincenzo Calderone)]
Current Topics in Medicinal Chemistry Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain
Current Topics in Medicinal Chemistry Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Natural Medicine:The Genus Angelica
Current Medicinal Chemistry Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Cefixime-induced Oromandibular Dystonia in an Adult: A Case Report
Current Drug Safety Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research Development of Radioligands for In Vivo Imaging of Type 1 Cannabinoid Receptors (CB1) in Human Brain
Current Pharmaceutical Design Spectral Investigations, Molecular Interactions and Electrochemical Studies of (2R)-(-)2-(2, 6-dimethylphenylaminocarbonyl)-1-methyl Piperidinium Chloride
Current Drug Therapy Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology